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Abstract The microencapsulation of three model drugs; metronidazole, paracetamol and
sulphapyridine into Poly (DL-Lactide-Co-Glycolide) (PLGA) scaffolds were probed using X-ray
Powder Diffraction (XRPD). Changes in the diffraction patterns of the PLGA scaffolds after
encapsulation was suggestive of a chemical interaction between the pure drugs and the scaffolds
and not a physical intermixture.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Following tremendous advancement in pharmaceutical and
medical research/technology, the use of biodegradable materi-
als/polymers such as Poly (DL-Lactide-Co-Glycolide) (PLGA)
nanoparticles/scaffolds/microparticles has become increasingly
essential as a drug delivery system.
Examples include, inclusion of pharmaceutical excipient
into polymeric matrices e.g. polymeric ﬁlms, microsphere
and nanospheres (Bibby et al., 2000), the use of nanoparticles
containing therapeutic agents for site-targeted drug delivery
and optimisation of drug treatment effects (Barzegar-Jalali
et al., 2012, 2008; Hornig et al., 2009; Lee, 2004) and use of
an electrospun Active Pharmaceutical Ingredient (API)-loaded
resorbable Poly Lactide (PLA) ﬁbre for local periodontitis
treatment (Markus et al., 2012; Jandt and Sigusch, 2009;
Balamurugan et al., 2008), etc.
PLGA has added advantages over other natural and syn-
thetic polymers; it is biocompatible, it can be used to synthesise
nano/micro-particles with tuneable physico-chemical proper-
ties and is an FDA (United States Food and Drug
Administration) approved polymer (Imbuluzqueta et al.,
2011; Ravi et al., 2008; Anderson and Shive, 1997.).
It not only increases the sustained release but also guards
against enzymatic degradation of drugs. (Sabzevari et al.,
2013; Tahara et al., 2011; Javadzadeh et al., 2010).
The relevance of the characterisation of the interaction
between polymer and drug(s) cannot be over emphasised
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because of its denotations on formulation outcomes, product
integrity, drug-release kinetics as well as probable polymorphic
transitions. (Singh and Kim, 2007; Hsiue et al., 1998; Jansen
et al., 1998; Katzhendler et al., 1998; Lorenzo-Lamosa et al.,
1998; Puttipipatkhachorn et al., 2001; Wong et al., 2002;
Takka, 2003).
This is particularly important in the pharmaceutical drug
development process where a drug product with optimal char-
acteristics must be identiﬁed in the early stages in order to pre-
vent unwanted ‘surprises’ in the later stages of development or
after the drug has been approved for usage. (Hilﬁker, 2006;
Preface, 2004).
The type of formulations used during the various stages of
drug development also determines the ﬁnal properties of the
drug product: for example when suspensions are used, particle
size must be controlled as this can affect bioavailability.
(Pirttima¨ki et al., 1993; Jain and Banga, 2010).
The purpose of this study is to analyse the nature of the
interaction (during microencapsulation) between three model
drugs; metronidazole, paracetamol, sulphapyridine (shown in
Fig. 1a–c respectively overleaf) and PLGA scaffolds using
X-ray Powder Diffraction (XRPD).
XRPD was particularly chosen to monitor the encapsula-
tion because of the superiority of the technique in differentiat-
ing between the structural properties of different materials.
(Justin, 1999; Cullity, 1995; Karjalainen et al., 2005).
More so all three drugs used in the study have reported
crystal structures (Ramukutty and Ramachandran, 2012;
Burley et al., 2007; Gharaibeh and Al-Ard, 2011; Basak
et al., 1848; Bar and Bernstein, 1985; Bernstein, 1988; Kirby
et al., 2011) while the PLGA scaffold is amorphous thus mak-
ing it easier to compare any changes that may arise in the X-
ray patterns after encapsulation with already published data.
Scanning Electron Microscopy (SEM) was also used to
probe the physical morphologies of the PLGA scaffolds before
and after encapsulations in order to corroborate data from the
XRPD studies.
2. Materials and methods
PVA (fully hydrolysed) and sulphapyridine were purchased
from Sigma Aldrich Co. 3050 Spruce Street, St. Louis, MO
63103 USA. PLGA was supplied by Evonik Degussa
Corporation, 750 Lakeshore parkway, Birmingham, AL.
35211 USA. Metronidazole was procured from Nacalai
Tesque Inc. Kyoto Japan; Paracetamol from R & M
Marketing Essex, UK. HPLC grade Dichloromethane
(DCM) was obtained from Fisher Scientiﬁc, Bishop Meadow
road, Loughborough, UK, LE11 5RG. Distilled water was
produced for this study using ELGA Purelab ﬂex
(Chemopharm Selangor, Malaysia), while Phosphate
Buffered Saline (PBS, (pH 7.4)) tablets were supplied by
Oxoid limited, Basingstoke, Hampshire, UK.
2.1. PLGA scaffolds preparation with drug encapsulation
The PLGA scaffolds incorporated with the model drugs were
prepared using the water in oil in water (w/o/w) emulsion tech-
nique (Kirby et al., 2011). 1 g of PLGA was weigh and dis-
solved in 5 ml of DCM, to this was added 250 ll of PBS
solution (the model drugs were dissolved in separate 100 ml
solutions of PBS at the following concentrations; metronida-
zole 0.5007% w/v, paracetamol 0.1409% w/v and sul-
phapyridine 0.09425 w/v according to their reported aqueous
solubilities) (Gouda et al., 1977; Jensen et al., 1990; Ribeiro
et al., 2012). The resulting mixture was homogenised
(Silverson L5M-A) at 9000 rpm for 2 min. The new PLGA/
DCM/PBS (plus model drug) mixture was then added to
200 ml of PVA solution which was then homogenised at
3000 rpm for 2 min. The double emulsion was then stirred
for 2 min at 300 rpm and the microparticles formed were
washed under a continuous ﬂow of water in a sieve (Fisher test
sieve number 230) and freeze dried.
2.2. XRPD analysis
XRPD patterns were collected on a Bruker D8 Advance
diffractometer system (Bruker AXS, Madison, WI, USA),
operating in a Bragg–Brentano geometry, at a wavelength (k)
of 1.54059 A˚, 40 kV voltage, and a current of 40 mA (with a
Cu Ka1 radiation source), using a LynxEye detector, samples
were contained in ﬂat Poly (methyl methacrylate) (PMMA)
sample holder. Data acquisition was done at 0.025/0.1 s step
size over a total period of 5 min.
2.3. Scanning Electron Microscopy (SEM)
SEM images were obtained using the LEO 1450 (LEO
Company LTD UK) variable pressure scanning electron
microscope, at an accelerated voltage of 10 kV.
3. Results and discussion
Figs. 2a–2c show overlay plots of the XRPD patterns obtained
before and after PLGA scaffold-drug encapsulation with
metronidazole, paracetamol and sulphapyridine respectively.
Under ordinary visual inspection of Figs. 2a–2c, the
changes in the XRPD patterns of the PLGA scaffolds are
not obvious; but on closer inspection, weak peaks (*) are evi-
dent on the X-ray patterns of the scaffolds after encapsulation
even at the extremely low drug concentration used as shown in
Figs. 3a–3c (black = PLGA scaffolds before encapsulation,
green = PLGA scaffolds after encapsulation, in all cases);
indicative of an interaction between the drugs and scaffolds.
Figure 1 Molecular structures of metronidazole (a), paracetamol
(b) and sulphapyridine (c).
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While the appearance of new (weak) peaks is apparent in the
encapsulated scaffolds as shown in Figs. 3a–3c, these peaks do
not occur in regions where the pure drugs exhibit characteristic
peaks i.e. 12.15, 13.80 (metronidazole), 23.40, 24.34 (parac-
etamol) and 19.59, 24.78 (sulphapyridine).
As such, these said peaks cannot be attributed to a physical
interaction between the drugs and the scaffolds. (Gouda et al.,
1977; Jensen et al., 1990; Ribeiro et al., 2012; Guns et al., 2010;
Lehto et al., 2006; Tita et al., 2011).
Figure 2a XRPD patterns of PLGA scaffolds before (black),
after encapsulation (green) and pure metronidazole (blue).
Figure 2b XRPD patterns of PLGA scaffolds before (black),
after (green) encapsulation and pure paracetamol (orange).
Figure 2c XRPD patterns of PLGA scaffolds before (black),
after (green) encapsulation and pure sulphapyridine (cyan).
Figure 3a XRPD offset patterns of metronidazole
encapsulation.
Figure 3b XRPD offset patterns for paracetamol encapsulation.
Figure 3c XRPD offset patterns for sulphapyridine
encapsulation.
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Similarly, Fig. 4a–d below show the SEM images of the
PLGA scaffolds before and after encapsulation with the model
drugs used in this study.
Fig. 4 above clearly shows that there is an interaction
between the PLGA scaffold and the model drugs as the scaf-
folds are markedly different before and after encapsulation.
In conclusion, it has been shown that metronidazole, parac-
etamol and sulphapyridine can be encapsulated into PLGA
scaffolds even at low concentration as permitted by their aque-
ous solubilities. XRPD has proven to be a veritable tool for
monitoring the observed encapsulation, although the appear-
ance of new/weaker peaks in the X-ray patterns of the encap-
sulated scaffolds cannot be adduced to a physical interaction
between the drugs and scaffold rather it is suggestive of a
stronger chemical interplay. SEM images also support the
deductions from the study, with the physical appearances of
the PLGA scaffolds signiﬁcantly different after encapsulation.
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